12:00 AM
Jan 30, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

AT9283: Phase I started

Cancer Research UK began a dose-escalation, U.K. Phase I trial to evaluate 72-hour IV infusions of AT9238 every 21 days in 15 pediatric patients ages 6 months to 18 years with...

Read the full 145 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >